Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | HPGD | P15428 | 6/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13232476 | 0.87 | KDM4E (0.52) | KDM4ESMN1; SMN2MEN1KMT2APLA2G2A | |
| SCHEMBL8737803 | 0.86 | DHODH (0.44) | KDM4ESMN1; SMN2MEN1KMT2APLA2G2A | |
| SCHEMBL15233650 | 0.83 | PDGFRB (0.37) | KDM4ESMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL8737548 | 0.83 | KDM4E (0.56) | KDM4ESMN1; SMN2MEN1KMT2APLA2G2A | |
| SCHEMBL8738290 | 0.83 | MEN1 (0.39) | KDM4ESMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL13262827 | 0.80 | MAPT (0.41) | KDM4ESMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL10041859 | 0.78 | LMNA (0.52) | KDM4ESMN1; SMN2PLA2G2AALDH1A1MAPT | |
| SCHEMBL15233645 | 0.76 | DHODH (0.42) | KDM4ESMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL15998647 | 0.73 | KDM4E (0.54) | KDM4ESMN1; SMN2MEN1KMT2APLA2G2A | |
| SCHEMBL1084619 | 0.72 | CYP1A2 (0.51) | SMN1; SMN2ALDH1A1MAPTHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029394-B2 | 2-phenyl-4-quinolones as anticancer agents | CHINA MEDICAL UNIVERSITY (TW) | 2015-05-12 | — | — | US | disclosed |
| US-9023866-B2 | 2-selenophene-4-quinolones as anticancer agents | CHINA MEDICAL UNIVERSITY (TW) | 2015-05-05 | — | — | US | disclosed |
| US-9023867-B2 | Hydrophilic derivatives of 2-selenophene-4-quinolones as anticancer agents | CHINA MEDICAL UNIVERSITY (TW) | 2015-05-05 | — | — | US | disclosed |
| US-20130252999-A1 | 2-PHENYL-4-QUINOLONES AS ANTICANCER AGENTS | CHINA MEDICAL UNIVERSITY (TW) | 2013-09-26 | — | — | US | disclosed |
| US-20130253006-A1 | 2-SELENOPHENE-4-QUINOLONES AS ANTICANCER AGENTS | CHINA MEDICAL UNIVERSITY (TW) | 2013-09-26 | — | — | US | disclosed |
| US-20130244983-A1 | NOVEL HYDROPHILIC DERIVATIVES OF 2-SELENOPHENE-4-QUINOLONES AS ANTICANCER AGENTS | CHINA MEDICAL UNIVERSITY (TW) | 2013-09-19 | — | — | US | disclosed |
| US-8440692-B2 | Hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents | CHINA MEDICAL UNIVERSITY (TW) | 2013-05-14 | — | — | US | disclosed |
| EP-2455369-A1 | Derivatives of 2-aryl-4-quinolones having an aminoalkyl group as anticancer agents | China Medical University (TW) | 2012-05-23 | — | — | EP | disclosed |
| US-20100168064-A1 | NOVEL HYDROPHILIC DERIVATIVES OF 2-ARYL-4-QUINOLONES AS ANTICANCER AGENTS | CHINA MEDICAL UNIVERSITY (TW) | 2010-07-01 | — | — | US | disclosed |
| WO-2008070176-A1 | NOVEL HYDROPHILIC DERIVATIVES OF 2-ARYL-4-QUINOLONES AS ANTICANCER AGENTS | CHINA MEDICAL UNIVERSITY (TW) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130244983-A1 | NOVEL HYDROPHILIC DERIVATIVES OF 2-SELENOPHENE-4-QUINOLONES AS ANTICANCER AGENTS | DHX30, SLC20A2, SLC20A1 | KDM4E 2738/4885SMN1; SMN2 4587/4885MEN1 3325/4885 |
| US-20130253006-A1 | 2-SELENOPHENE-4-QUINOLONES AS ANTICANCER AGENTS | DDX5, DHX30, PPIP5K2 | KDM4E 2292/4885SMN1; SMN2 4456/4885MEN1 2925/4885 |
| US-20100168064-A1 | NOVEL HYDROPHILIC DERIVATIVES OF 2-ARYL-4-QUINOLONES AS ANTICANCER AGENTS | DHX30, SLC20A2, DDX20 | KDM4E 2310/4885SMN1; SMN2 4695/4885MEN1 3774/4885 |
| US-20130252999-A1 | 2-PHENYL-4-QUINOLONES AS ANTICANCER AGENTS | PPIP5K2, DDX5, DHX30 | KDM4E 1763/4885SMN1; SMN2 4616/4885MEN1 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.